DELZICOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Delzicol, and when can generic versions of Delzicol launch?
Delzicol is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in DELZICOL is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Delzicol
A generic version of DELZICOL was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.
Summary for DELZICOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 181 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,145 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DELZICOL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DELZICOL |
| What excipients (inactive ingredients) are in DELZICOL? | DELZICOL excipients list |
| DailyMed Link: | DELZICOL at DailyMed |
Recent Clinical Trials for DELZICOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 3 |
| Holy Stone Healthcare Co., Ltd | Phase 1 |
Pharmacology for DELZICOL
| Drug Class | Aminosalicylate |
Paragraph IV (Patent) Challenges for DELZICOL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| DELZICOL | Delayed-release Capsules | mesalamine | 400 mg | 204412 | 1 | 2014-06-17 |
US Patents and Regulatory Information for DELZICOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | DELZICOL | mesalamine | CAPSULE, DELAYED RELEASE;ORAL | 204412-001 | Feb 1, 2013 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DELZICOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | DELZICOL | mesalamine | CAPSULE, DELAYED RELEASE;ORAL | 204412-001 | Feb 1, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | DELZICOL | mesalamine | CAPSULE, DELAYED RELEASE;ORAL | 204412-001 | Feb 1, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | DELZICOL | mesalamine | CAPSULE, DELAYED RELEASE;ORAL | 204412-001 | Feb 1, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DELZICOL
See the table below for patents covering DELZICOL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 60001283 | ⤷ Try a Trial | |
| Spain | 2191595 | ⤷ Try a Trial | |
| Japan | H0414083 | ⤷ Try a Trial | |
| Finland | 833099 | ⤷ Try a Trial | |
| European Patent Office | 0097651 | DELAYED RELEASE ORAL DOSAGE FORMS CONTAINING 5-ASA | ⤷ Try a Trial |
| European Patent Office | 1045000 | Films d'éther de cellulose (Cellulose ether films) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
